NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/29/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization14.64 mln
Float3.49 mln
Earnings Date08/05/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-5.41
Highly reliable
Relative Strength
76
/ 100
Strongly outperforming
Debt / Equity
0.00
Debt-free
ROE
-61.69
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Cyclerion Therapeutics is a Cambridge, Massachusetts-based drug development company focused on treating serious conditions affecting the heart, kidneys, and nervous system. The company's two lead compounds, Olinciguat and Praliciguat, work by targeting a key biological pathway that regulates blood flow and organ function. Olinciguat is currently being tested in clinical trials for cardiovascular disease, while Praliciguat is being developed for a rare kidney condition in partnership with Akebia, who holds commercialization rights. Founded in 2018, Cyclerion is building a pipeline of medicines designed to address diseases with few effective treatment options.
